Loading...
Loading...
Browse all stories on DeepNewz
VisitWhich drug will TxGNN identify as the most promising repurposing candidate by September 25, 2025?
Drug A • 25%
Drug B • 25%
Drug C • 25%
Other • 25%
Publication in a peer-reviewed medical journal or official press release from the research team
AI Model TxGNN Repurposes Drugs for 17,080 Rare Diseases
Sep 25, 2024, 03:30 PM
Researchers have developed TxGNN, an AI-driven model designed to repurpose existing drugs for the treatment of rare diseases. This model, recently published in Nature Medicine, identifies potential therapeutic candidates for over 17,080 diseases, including those with no current treatment options. TxGNN leverages a medical knowledge graph to rank drugs as potential indications and contraindications, offering new hope for approximately 300 million people worldwide affected by rare diseases. The model's zero-shot framework allows it to predict drug candidates without prior examples, significantly accelerating the drug discovery process. TxGNN was trained on data from 7,957 drugs.
View original story
Drug A • 25%
Drug B • 25%
Drug C • 25%
Other • 25%
Yes • 50%
No • 50%
Genetic Disorders • 25%
Infectious Diseases • 25%
Neurological Disorders • 25%
Other • 25%
Respiratory drug • 25%
Immunology drug • 25%
Vaccine • 25%
Other • 25%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Yes • 50%
No • 50%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Migraine medication • 25%
COVID-19 medication • 25%
Flu medication • 25%
Respiratory illness medication • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
1-5 treatments • 25%
More than 15 treatments • 25%
11-15 treatments • 25%
6-10 treatments • 25%